Morgan Stanley turns bearish on Novo Nordisk amid Semaglutide patent expiries
Morgan Stanley warned Novo Nordisk’s heavy reliance on Semaglutide could become a headwind as key patents begin to expire in the early 2030s.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.